The aim of this study was to evaluate the impact of pretransplant transfusion of packed red cells (PRCs) on outcome after allogeneic stem cell transplantation (SCT) in severe aplastic anemia (SAA). A total of 221 adult SAA patients receiving allogeneic SCT were analyzed. The patients were divided into two groups according to the amount of pretransplant transfusion before SCT: the low transfusion group (⩽32 PRC units, n = 164) and the high transfusion group (432 PRC units, n = 57). The incidence of engraftment failure was not different between the two groups. The incidence of acute GvHD (grades II-IV) was higher in the high transfusion group than in the low transfusion group (P = 0.04), and the incidences of chronic extensive GVHD were not significantly different (P = 0.136). The high transfusion group had higher 5-year transplant-related mortality (TRM) (24.8% vs 6.8%, P o0.001) and lower overall survival (OS) (72.3% vs 91.9%, P o0.001) than those in the low transfusion group. Multivariate analysis revealed that the high transfusion group and unrelated donor type were independent prognostic factors affecting OS. These results indicate that a history of higher pretransplant transfusion of PRCs was associated with increased TRM and decreased OS, suggesting that iron overload had a negative impact on outcome after SCT in SAA.
INTRODUCTION
Severe aplastic anemia (SAA) is a life-threatening bone marrow failure disorder. For patients with AA requiring treatment, immunosuppressive therapy or allogeneic stem cell transplantation (SCT) is recommended depending on disease severity, patient age and availability of an HLA-identical donor. 1, 2 In addition, many patients with SAA require blood transfusions for supportive management.
Regular transfusions of packed red cells (PRCs) lead to the development of iron overload that is known to increase the risk of transplant-related mortality (TRM) and other complications including fungal infections, hepatic dysfunction and hepatic venoocclusive disease after SCT. [3] [4] [5] [6] [7] The adverse prognostic impacts of iron overload have been evaluated for patients who underwent transplantation for various hematologic disorders including thalassemia, myelodysplastic syndrome (MDS) and acute leukemia. 3, [8] [9] [10] [11] [12] [13] However, the prognostic impact of pretransplant transfusion history of PRC on outcome in SAA had remained unclear.
We performed a retrospective study to evaluate the prognostic significance of pretransplant transfusion in 221 adult patients with SAA undergoing allogeneic SCT from a matched sibling or an unrelated donor.
MATERIALS AND METHODS

Patient selection
The present study analyzed 221 consecutive adult patients who underwent allogeneic SCT for SAA at Seoul St Mary's Hospital between 1995 and 2007.
To evaluate the prognostic impact of pretransplant transfusion history on outcome after SCT, the study period was chosen based on the absence of proper iron chelation therapy (ICT). The patients with available pathology reports of bone marrow biopsy for excluding hypocellular MDS were eligible for the present study. To identify the optimal cutoff in the amount of pretransplant transfusion for predicting overall survival (OS) after SCT, we performed a receiver operating characteristic curve analysis and applied different cutoff levels iteratively in steps of 1 PRC unit. A cutoff of 432 units was chosen with significantly lower probability of OS. A total of 164 patients who received ⩽32 PRC units of transfusion (the low transfusion group) were compared with 57 patients who received 432 PRC units of transfusion before SCT (the high transfusion group) with respect to transplant outcome. In this study, serum ferritin data were not available. The institutional review board of The Catholic University of Korea approved the research protocol for data analysis.
Preparative regimen and GvHD prophylaxis
The conditioning regimen and GvHD prophylaxis have been described elsewhere. [14] [15] [16] Briefly, before 2003, the conditioning regimen for the related donor setting consisted of cyclophosphamide 50 mg/kg once daily IV for 4 days (total dose 200 mg/kg), rabbit antithymocyte globulin (thymoglobulin; Genzyme, Cambridge, MA, USA) 1.25 mg/kg IV on days − 6, − 4 and − 2, and procarbazin 6.25 mg/kg PO in divided doses daily for 6 days. After 2004, the conditioning regimen for the related donor setting consisted of fludarabine 30 mg/m 2 once daily for 6 days, cyclophosphamide 50 mg/kg once daily for 2 days and 2.5 mg/kg antithymocyte globulin on days − 8, − 6, − 4 and − 2. The conditioning regimen for the unrelated donor setting was cyclophosphamide 60 mg/kg for 2 days, followed by TBI at a dose of 8 to 12 Gy using a fraction size of 2 Gy. G-CSF-mobilized PBSCs or bone marrow stem cells were administered on day 0. A total of 40 patients received both bone marrow and CD34(+)-purified PBSCs. 17 GvHD prophylaxis consisted of cyclosporine and short-course methotrexate (10 mg/m 2 IV bolus on days +1, +3, +6 and +11) for related SCT and tacrolimus and short-course methotrexate (5 mg/m 2 IV bolus on days +1, +3, +6 and +11) for unrelated SCT. G-CSF (5 μg/kg/day) was administered subcutaneously to all patients from day +7 after transplantation until reaching an ANC of 43.0 × 10 9 /L. The other general procedures of transplantation were performed as described in a previous report. 14 
Definitions
Failure to engraft by day 28 was considered primary engraftment failure. Secondary engraftment failure was defined as an initial engraftment with documented donor-derived hematopoiesis followed by loss of graft function. Neutrophil engraftment was defined as an ANC of ⩾ 0.5 × 10 9 /L during the first of 3 consecutive days. Platelet engraftment was defined as a platelet count of ⩾ 20 × 10 9 /L without transfusion support during the first of 5 consecutive days. Acute and chronic GvHD were graded according to the clinical consensus criteria. 18, 19 OS was calculated from the day of transplantation, with patients alive at the time of the last follow-up being administratively censored, and TRM was defined as death because of any cause other than graft failure.
Statistical analysis
End points were OS, TRM and graft failure. The survival curves for OS were plotted using the Kaplan-Meier method and were compared using the log-rank test. Curves for TRM and graft failure were plotted according to cumulative incidence estimates and were compared using the Gray test. The prognostic significance of presenting and transplant covariates affecting OS was determined using the Cox proportional hazards model. Factors with an associated P-value of o0.05 as determined by the likelihood ratio test using two-tailed significance testing were deemed to be statistically significant. The prognostic significance of covariates affecting TRM and graft failure was determined using the proportional hazards model for subdistribution of competing risks. Statistical analyses were performed using the Statistical Package for the Social Sciences (version 13.0; SPSS, Inc., Chicago, IL, USA), and cumulative incidence functions were computed with R functions from competing risks analysis libraries (R software, version 2.9.1; R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Patients and transplantation characteristics A total of 221 adult patients with SAA who received SCT from a matched sibling (n = 171), an HLA-matched unrelated donor (n = 34) and an HLA-mismatched unrelated donor (n = 16) were retrospectively analyzed in the present study. In this study, the patients received SCT without proper ICT because deferasirox was not available in Korea during the study period. The median age of the 113 males and 108 females was 29 years (range, 15-53 years). For the comparative analysis, there were 164 patients who received ⩽32 PRC units of transfusion (the low transfusion group) and 57 patients who received 432 PRC units of transfusion before SCT (the high transfusion group). The time from diagnosis to transplant in the high transfusion group was longer than that of the low transfusion group (Po0.001). In the low transfusion group, there were more transplants from related donors and more transplants using bone marrow as the source of the graft. No other pretransplant characteristics differed significantly between the two groups ( Table 1) .
Engraftment
All patients except one (99.5%) achieved engraftment. Primary engraftment failure developed in one patient, who received 150 PRC units of transfusion before transplant. Secondary engraftment failure was noted in 12 patients (9/164 patients, 5.5% in the low transfusion group, 3/57 patients, 5.3% in the high transfusion group), and there was no statistically significant difference between groups (P = 1.0; Table 2 ). All patients with secondary engraftment failure had received 42.0 × 10 6 /kg CD34 + cells, except one patient, who was infused with 1.0 × 10 6 /kg. Ten patients received an additional infusion of stem cells; among them, three patients died from pneumonia (n = 2) or brain abscess (n = 1).
Impact of pretransplant transfusion on GvHD
Of the 220 patients who achieved donor engraftment, acute GvHD (⩾ Grade II) developed in 45 of 164 patients (27.4%) in the low transfusion group and 24 of 56 (42.8%) in the higher transfusion group (P = 0.032). We observed that the incidence of acute GvHD of grades II to IV was higher in the high transfusion group than in the low transfusion group, with a statistically significant difference. Of the 206 evaluable patients who achieved durable engraftment and survived of 4100 days, chronic extensive GvHD developed in 49 patients (23.8%). There was no statistical difference in the incidence of chronic extensive GvHD between the high transfusion group and the low transfusion group (31.9% vs 21.4%, P = 0.136; Table 2 ).
Impact of pretransplant transfusion on transplant outcome After a median follow-up of 70.3 (range, 1.0-181.8) months in the low transfusion group and 64.6 (2.5-157.4) months in the high Abbreviations: BM = bone marrow; PRC = packed red blood cell.
Transfusion history and outcome after SCT in SAA S-E Lee et al transfusion group, 192 patients (86.9%) (151/164 patients (92.1%) in the low transfusion group and 41/57 (71.9%) in the high transfusion group) were alive. The high transfusion group had a higher 5-year cumulative incidence of TRM than did the low transfusion group (24.8 ±5.8% vs 6.8 ± 2.0%, P o0.001), and the estimated 5-year OS values in the two groups were significantly different (91.9 ± 2.1% in the low transfusion group vs 72.3 ± 6.2% in the high transfusion group, P o 0.001; Table 2 and Figure 1) . In a separate analysis according to donor type, the high transfusion group showed significantly lower OS and increased risk of TRM compared with the low transfusion group in both related and unrelated SCT (Figure 2 ).
Factors affecting transplant outcome Potential variables influencing both OS and TRM were patient sex, donor type, time from diagnosis to transplant, and amount of pretransplant transfusion (Table 3) . According to multivariate analysis, unrelated donor type (hazard ratio, 2.22; 95% confidence interval, 1.04-4.73; P = 0.039) and high transfusion group (hazard ratio, 3.07; 95% confidence interval, 1.41-6.69; P = 0.005) were independent variables affecting OS. In terms of TRM, unrelated donor type (hazard ratio, 2.77; 95% confidence interval, 1.27-6.05; P = 0.011) and high transfusion group (hazard ratio, 3.08; 95% confidence interval, 1.39-6.80; P = 0.005) were independent variables according to multivariate analysis ( Table 4 ).
Cause of death Table 5 shows the causes of death according to pretransplant transfusion groups; 3 patients died after graft failure (2 patients in the low transfusion group and 1 patient in the high transfusion group). Infection-related mortalities, including secondary infection to GvHD, occurred more frequently in the high transfusion group (7/164, 4.3% vs 10/57, 17.5%, P = 0.001).
DISCUSSION
Previous studies have documented the adverse prognostic impact of iron overload in patients undergoing allogeneic SCT for hematological malignancies and MDS. 20 Altes et al. 4 evaluated the toxic effect of iron overload by measuring pre-conditioning ferritin level and transferrin saturation in patients with various hematological malignancies. In their study, ferritin and transferrin saturation acted as independent predictive factors influencing TRM and OS. Another study with 190 patients also showed that elevated serum ferritin adversely affected OS and increased the likelihood of acute GvHD and blood stream infection after allogeneic SCT. 3 The above studies were performed in patients with various hematologic malignancies, and various regimens for conditioning and GVHD prophylaxis were used. Recently, several Abbreviations: E/N = number of events/number of evaluable patients; PRC = packed red blood cell; TRM = transplant-related mortality.
studies including homogenous disease groups have been performed. Armand et al. 8 reported that iron overload had an important role in transplantation outcome for patients with acute leukemia and MDS in terms of OS, disease-free survival and TRM. In addition, their study showed that patients with high ferritin had a trend toward increased risk of venoocclusive disease. 8 A few studies were conducted to evaluate the prognostic impact of iron overload in MDS. 9, 11 In those studies, pretransplant transfusion history and secondary iron overload were found to possibly contribute to poor transplantation outcome.
However, until now, for patients with SAA who require blood transfusions as supportive management, the prognostic impact of pretransplant transfusion history after allogeneic SCT had remained unclear. Considering the disease characteristics of SAA requiring transfusion, a detailed analysis is needed to clarify the impact of pretransplant transfusion on outcome after allogeneic SCT in SAA.
Compared with many earlier reports in which serum ferritin was used as a marker of iron overload, 3, 8, 10 this study evaluated the relationship between pretransplant transfusion history and transplantation outcome. This relationship was chosen based on the fact that each PRC unit adds ∼ 200-250 mg of iron to the total iron pool in the body. Furthermore, iron overload can occur after ∼ 20 transfusions, 21 and the number of transfusions correlates with serum ferritin and hepatic iron. 22, 23 A single measurement of serum ferritin as a marker of iron overload should be interpreted with caution because high ferritin level at the time of transplant can be due not only to transfusion amount, but also to inflammation or infection. 24 We clarified that more pretransplant transfusion had a significantly negative impact in terms of increased risk of TRM and lower OS than in patients with lesser transfusion history. In multivariate analysis, donor type was significantly associated with transplant outcome, whereas disease duration did not show a different outcome. Therefore, we performed a separate analysis according to donor type that revealed that the negative impact of higher pretransplant transfusion was maintained after adjusting for donor type (related vs unrelated), indicating that higher pretransplant transfusion was an independent predictor apart from the other variables (Figure 2) .
Our results also suggest that a higher pretransplant transfusion history of PRC might be a risk factor of acute GvHD. This finding is supported by a few other studies. Alessandrino et al. 11 found that transfusion dependency was a risk factor of acute GvHD in patients with MDS. One possible hypothesis is that free iron radical-mediated injury may increase the susceptibility of the organs to GvHD. In addition, Platzbecker et al. 9 showed that transfusion burden was associated with a greater probability of severe acute GvHD in MDS. In contrast, some studies have suggested that hyperferritinemia was neither associated with an increased risk of acute GvHD nor related to lower incidence of acute GvHD. 8, 25 In this study, the patients in the high transfusion group were more likely to undergo transplantation from an unrelated donor that can influence the occurrence of acute GvHD. Thus, the clinical impact of transfusion burden on the occurrence of acute GvHD has to be interpreted cautiously.
Previously, a few studies have explained that the cause of the poor outcomes seen in patients with SAA who had received numerous transfusions before SCT was that receiving a large number of transfusions was associated with increased risk of Abbreviations: BM = bone marrow; OS = overall survival; PRC = packed red blood cell; TRM = transplant-related mortality. Abbreviations: CI = confidence interval; HR = hazard ratio; OS = overall survival; PRC, packed red blood cell; TRM = transplant-related mortality.
rejection, and early transplantation was recommended before allosensitization could occur because of heavy transfusion. 26 Although the current transfusion policy calls for use of a leukocyte-depleted filter and irradiation of blood products to reduce the risk of rejection, our results showed that early transplantation can improve transplant outcome, because PRC transfusion increases TRM rate without increasing graft failure, and this elevated rate is translated into decreased OS. However, because this study lacks serum ferritin data, further studies providing direct data that worse outcome of patients with higher transfusion results from iron overload are needed. In this study, the patients received SCT in the pre-deferasirox era, when ICT was not widely used for the treatment of patients with iron overload because of poor compliance with deferoxamine treatment. These findings apply to the patients in this study and in our previous studies. 23, 27 Recently, an oral chelating agent, deferasirox, has become available. Therefore, intensive ICT for patients who received a large transfusion amount (420 PRC units of PRC transfusion) and in those with serum ferritin level 41000 ng/mL may improve the transplantation outcomes. 28 Notably, most of the patients who had to use an unrelated donor were transfusion dependent after failed immunosuppressive therapy. For such patients, the transplantation outcomes would be expected to be improved by pretransplant intensive ICT. 10 In this study, a higher infection-related mortality was observed in the high transfusion group compared with that of the low transfusion group, suggesting the need for further studies focusing on whether pretransplant ICT can reduce the incidence of infectious complications or infection-related TRM after transplantation.
In conclusion, although our study was limited by its retrospective nature and lack of serum ferritin data from the pre-deferasirox era, we suggest that pretransplant PRC transfusion is independently associated with outcome after allogeneic SCT in SAA. The negative impact of pretransplant transfusion was observed in adult patients with SAA who had not received optimal ICT. Future studies aimed at clarifying the clinical effects of ICT before SCT in reducing TRM and improving the transplantation outcome in patients with SAA are needed. Abbreviations: MDS = myelodysplastic syndrome; PRC, packed red blood cell; VOD = venoocclusive disease.
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